Drug Profile
Research programme: polo-like kinase 3 protein inhibitors - Clinical Data
Alternative Names: PLK3 protein inhibitors - Clinical DataLatest Information Update: 26 Apr 2012
Price :
$50
*
At a glance
- Originator Avalon Pharmaceuticals
- Developer Clinical Data
- Class Small molecules
- Mechanism of Action Protein-serine-threonine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Apr 2012 Discontinued for Cancer in USA (unspecified route)
- 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
- 29 May 2009 Avalon Pharmaceuticals has been acquired and merged into Clinical Data